Acute Myeloid Leukemia as a Model for Cancer Therapy

por Ravandi, Farhad
Publicado 2012

Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?

por Swaminathan, Mahesh, Ravandi, Farhad
Publicado 2023

How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?

por Short, Nicholas J., Ravandi, Farhad
Publicado 2019

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm

por Daver, Naval, Venugopal, Sangeetha, Ravandi, Farhad
Publicado 2021

Acute promyelocytic leukemia current treatment algorithms

por Yilmaz, Musa, Kantarjian, Hagop, Ravandi, Farhad
Publicado 2021

Maintenance therapy in acute myeloid leukemia: advances and controversies

por Senapati, Jayastu, Kadia, Tapan M., Ravandi, Farhad
Publicado 2023

Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors

por Short, Nicholas J., Nguyen, Daniel, Ravandi, Farhad
Publicado 2023

Editorial: Acute Promyelocytic Leukemia — Towards A Chemotherapy-Free Approach to Cure in All Patients

por Gill, Harinder, Kwong, Yok-Lam, Ravandi, Farhad
Publicado 2022

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia

por Briski, Robert, Garcia-Manero, Guillermo, Kantarjian, Hagop, Ravandi, Farhad
Publicado 2023

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia

por Short, Nicholas J., Kantarjian, Hagop, Ravandi, Farhad, Daver, Naval
Publicado 2019

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions

por Samra, Bachar, Jabbour, Elias, Ravandi, Farhad, Kantarjian, Hagop, Short, Nicholas J.
Publicado 2020

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia

por Aitken, Marisa J. L., Ravandi, Farhad, Patel, Keyur P., Short, Nicholas J.
Publicado 2021

Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia

por Guerra, Veronica A., Jabbour, Elias J., Ravandi, Farhad, Kantarjian, Hagop, Short, Nicholas J.
Publicado 2019

Resistance to targeted therapies: delving into FLT3 and IDH

por Desikan, Sai Prasad, Daver, Naval, DiNardo, Courtney, Kadia, Tapan, Konopleva, Marina, Ravandi, Farhad
Publicado 2022

The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades

por Jabbour, Elias, Short, Nicholas J., Jain, Nitin, Haddad, Fadi G., Welch, Mary Alma, Ravandi, Farhad, Kantarjian, Hagop
Publicado 2023

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia

por Pasvolsky, Oren, Daher, May, Alatrash, Gheath, Marin, David, Daver, Naval, Ravandi, Farhad, Rezvani, Katy, Shpall, Elizabeth, Kebriaei, Partow
Publicado 2022

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia

por Bidikian, Aram, Kantarjian, Hagop, Jabbour, Elias, Short, Nicholas J., Patel, Keyur, Ravandi, Farhad, Sasaki, Koji, Issa, Ghayas C.
Publicado 2022

Acute myeloid leukemia: current progress and future directions

por Kantarjian, Hagop, Kadia, Tapan, DiNardo, Courtney, Daver, Naval, Borthakur, Gautam, Jabbour, Elias, Garcia-Manero, Guillermo, Konopleva, Marina, Ravandi, Farhad
Publicado 2021

P585: IMPACT OF MYELOID MUTATION PROFILE ON PCR RESPONSES AND SURVIVAL IN PATIENTS WITH CORE-BINDING FACTOR AML TREATED WITH FLAG BASED REGIMES

por Senapati, Jayastu, Bidikian, Aram, Ravandi, Farhad, Kadia, Tapan, Dinardo, Courtney, Garcia-Manero, Guillermo, Daver, Naval, Pemmaraju, Naveen, Jabbour, Elias, Brandt, Mark, Borthakur, Gautam
Publicado 2023

A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure

por Raza, Azra, Ravandi, Farhad, Rastogi, Anjay, Bubis, Jeffrey, Lim, Seah H., Weitz, Ilene, Castro-Malaspina, Hugo, Galili, Naomi, Jawde, Rony Abou, Illingworth, Andrea
Publicado 2013